Progress in the Treatment of Metastatic Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast, a panel of experts discusses a range of topics relating to metastatic melanoma, including new treatment approaches, clinical trial updates, and managing side effects and pain. The participants on the panel were: Paul Chapman, MD, of the Memorial Sloan-Kettering Cancer Center; Gregory Daniels, MD, PhD, of the University of California San Diego; Mario Lacouture, MD, of the Memorial Sloan-Kettering Cancer Center; and Carolyn Messner, DSW, MSW, of CancerCare.
 
To listen to the podcast, click here.
Related Articles
A combination of vemurafenib (Zelboraf) and experimental drug cobimetinib significantly reduces the development of secondary skin cancer.
The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.
RX-3117 maintains anti-tumor activity in cancer cell lines that are resistant to gemcitabine.
Latest Issues
$auto_registration$